NCT03842800View on ClinicalTrials.gov

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Cognitive Impairment
Interventions
OTHER

MRI

Patients and volunteers will receive an MRI.

DRUG

Ketamine

Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.

Trial Locations (1)

06520-8043

Magnetic Resonance Research Center, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03842800 - Characterizing Clinical and Pharmacological Neuroimaging Biomarkers | Biotech Hunter | Biotech Hunter